Rockwell Medical, Inc. (RMTI) stock
RMTINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 11/3080% below fair value
$6.61−0.15 (-2.22%)
Close on Nov 17, 2026Market cap $26.64MP/E –Yield –
Rockwell Medical total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Rockwell Medical's total debt was $9.00M at Jun 30, 2026. For fiscal 2025 it was $8.83M, up 4.2% from the year before. The highest annual figure on record is $20.95M in fiscal 2020.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.83M | +4.2% |
| FY2024 | Dec 31, 2024 | $8.47M | +2.2% |
| FY2023 | Dec 31, 2023 | $8.29M | -9.7% |
| FY2022 | Dec 31, 2022 | $9.19M | -55.3% |
| FY2021 | Dec 31, 2021 | $20.57M | -1.8% |
| FY2020 | Dec 31, 2020 | $20.95M | – |
| FY2019 | Dec 31, 2019 | $0 | -100.0% |
| FY2013 | Dec 31, 2013 | $20.23M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $9.00M | +4.1% |
| Q1 FY2026 | Mar 31, 2026 | $8.91M | +4.1% |
| Q4 FY2025 | Dec 31, 2025 | $8.83M | +4.2% |
| Q3 FY2025 | Sep 30, 2025 | $8.74M | +4.2% |
| Q2 FY2025 | Jun 30, 2025 | $8.65M | +4.3% |
| Q1 FY2025 | Mar 31, 2025 | $8.56M | +3.6% |
| Q4 FY2024 | Dec 31, 2024 | $8.47M | +2.2% |
| Q3 FY2024 | Sep 30, 2024 | $8.38M | -6.5% |
| Q2 FY2024 | Jun 30, 2024 | $8.30M | -11.5% |
| Q1 FY2024 | Mar 31, 2024 | $8.27M | -10.9% |
| Q4 FY2023 | Dec 31, 2023 | $8.29M | -9.7% |
| Q3 FY2023 | Sep 30, 2023 | $8.96M | -36.4% |
| Q2 FY2023 | Jun 30, 2023 | $9.37M | -39.5% |
| Q1 FY2023 | Mar 31, 2023 | $9.28M | -49.6% |
| Q4 FY2022 | Dec 31, 2022 | $9.19M | -55.3% |
| Q3 FY2022 | Sep 30, 2022 | $14.09M | -33.6% |
| Q2 FY2022 | Jun 30, 2022 | $15.50M | -26.7% |
| Q1 FY2022 | Mar 31, 2022 | $18.41M | -12.5% |
| Q4 FY2021 | Dec 31, 2021 | $20.57M | -1.8% |
| Q3 FY2021 | Sep 30, 2021 | $21.23M | +1.8% |
| Q2 FY2021 | Jun 30, 2021 | $21.13M | +1.8% |
| Q1 FY2021 | Mar 31, 2021 | $21.04M | +1.7% |
| Q4 FY2020 | Dec 31, 2020 | $20.95M | – |
| Q3 FY2020 | Sep 30, 2020 | $20.86M | – |
| Q2 FY2020 | Jun 30, 2020 | $20.76M | – |
| Q1 FY2020 | Mar 31, 2020 | $20.68M | – |
| Q4 FY2019 | Dec 31, 2019 | $0 | – |
See a number that looks wrong?